Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 3 1

Status

Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 4Uveal Melanoma 1

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Specimen Handling 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × lifileucel × Clear all
NCT05607095 2026-05-28

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
30 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT05176470 2026-02-24

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Ohio State University Comprehensive Cancer Center

Phase 1 Active not recruiting
2 enrolled
Dermatologic

Melanoma

NCT05640193 2025-09-12

A Study of LN-144 in People With Metastatic Melanoma to the Brain

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
10 enrolled
Dermatologic

Melanoma

NCT06190249 2025-06-05

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Case Comprehensive Cancer Center

Phase 1 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡